Bayer's $7.25B Roundup Settlement Has a Cost for Opting Out

Main Points Summary

Bayer's proposed $7.25 billion class-action settlement for claims that its Roundup weedkiller causes cancer has received preliminary court approval. The agreement is notably structured with financial disincentives to prevent plaintiffs from opting out and pursuing individual lawsuits.

Settlement Structure Overview

The deal includes specific clauses designed to ensure broad participation. A key provision denies legal fees to attorneys if more than 25 of their clients opt out. Furthermore, Bayer can reduce its total payout by up to $400 million if more than 650 plaintiffs reject the settlement. The company also retains the right to terminate the agreement entirely if an 'excessive' number of claimants opt out.

Financial Implications

This settlement aims to resolve a significant portion of the approximately 65,000 claims Bayer faces in the U.S. While the company admits no wrongdoing, it seeks to contain litigation risk. Payouts for class members will vary based on factors like age and exposure, with average awards estimated between $10,000 and $165,000. Plaintiffs have a deadline to decide whether to accept the deal or opt out.

Conclusion

The settlement's framework places significant pressure on plaintiffs and their legal representatives to accept the terms. The decision for many will weigh the certainty of a payout against the potential for a larger award through individual litigation, a risk amplified by a pending U.S. Supreme Court review that could impact future claims.

FAQ

Q: What is the total value of the proposed Roundup settlement?
A: The proposed class-action settlement is valued at $7.25 billion to resolve current and future claims.

Q: How does the settlement discourage plaintiffs from opting out?
A: It denies legal fees to lawyers with more than 25 opt-out clients and allows Bayer to reduce the total fund if over 650 plaintiffs reject the deal.

Source: Investing.com